Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A study of the activity of a new corticosteroid for topical use, betamethasone in a propylene glycol vehicle, is reported. The trial was open and included 52 cases. These were mainly severe and chronic cases of atopic dermatitis, psoriasis and intractable prurigos resulting from various causes. The overall results were quite satisfactory, with 80% of good or very good responses. Itching was the feature most frequently improved by this treatment. If atopic dermatitis and psoriasis reacted well the response was particularly satisfactory in lichen planus. Evidence indicating an important effect on adrenal gland function is pointed out. This effect was demonstrated either by decreased serum cortisol levels or by decreased urinary excretion of steroids. This point should be carefully monitored, especially when treating patients with extensive skin disease. Therapy should be discontinued very progressively.
 ...
PMID:[A clinical trial of a new class IV corticosteroid for topical use. Fifty-two case-reports (author's transl)]. 627 Aug 23

This clinical evaluation to determine the long-term therapeutic efficacy and tolerability of 0.05% halometasone ointment was carried out in fifty patients (forty-one with psoriasis and nine with chronic eczema) by seven dermatologists in Austria and Switzerland. The ages ranged from 19 to 76 years and the total duration of illness was more than 5 years in 62% of the trial population. The duration of treatment varied from 38 to 103 days (38-60 days in twenty-two patients, 61-90 days in twenty-five patients and 91-103 days in three patients). All patients received two non-occlusive applications of halometasone ointment per day. In this long-term study halometasone ointment exhibited very satisfactory therapeutic efficacy and very good tolerability. 'Good' to 'very good' results were reported in 73% and 89% of the patients with psoriasis and chronic eczema treated with halometasone ointment, respectively. Adverse effects were reported in only two (4%) patients who had transient itching at the site of application. Neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed in this study, nor were any instances of contact skin allergy reported.
 ...
PMID:Clinical evaluation on the long-term use of halometasone ointment in chronic eczema and psoriasis. 633 91

A personal experience on 495 patients affected by several forms of psoriasis and its answer to the treatment with anapsos (Polypodium Leucotomos Extract) is presented. The whitenings between 80% and 100% of the affected skin were achieved on 304 patients (61.41%); 46 patients whitened between 30% and 80% of their lesions, 15 obtained null results and only 11 had relapses. It is remarkable the high number of abandonments to treatment which came at 119 patients (24.04%) due to slowness of process and other reasons probably. The association with PUVA which shortens the treatment and gives other advantages is pointed out as positive. The average time of treatment was 6 months, and daily doses were from 80 mg. and 720 mg. depending on age, weight and treatment phase. Side effects appeared in two patients only: one with intense pruritus and the other one with gastric disturbances. In both cases, these side effects disappeared when the treatment was interrupted.
 ...
PMID:[2 years personal experience in anapsos treatment of psoriasis in various clinical forms]. 634 43

A trial was carried out in 60 patients with relatively stable psoriasis to compare the effectiveness, tolerance and cosmetic properties of dithranol in a cream base (0.1% and 0.25%) or in the form of a soft paraffin ointment (0.25%). Patients were assigned at random to receive treatment with one or other of the three formulations, applied once daily, over a period of 4 weeks. Assessments were made initially and after 2 and 4 weeks of induration, redness, scaling and pruritus and during the trial of staining of clothes and linen, skin discolouration and burning. There was no significant difference in effect between dithranol cream 0.25% and dithranol ointment 0.25%, while both showed a better effect than dithranol cream 0.1% (p less than 0.05). The dithranol cream preparations were significantly better (p less than 0.05) than dithranol ointment 0.25% regarding all the cosmetic variables after 2 as well as after 4-weeks' treatment. The same applied to the patients' overall evaluation of the cosmetic acceptability. Three patients in the dithranol ointment group were considered as treatment failures. One of them refused to continue with the treatment due to burning and another due to burning and staining.
 ...
PMID:A comparative study of dithranol cream, 0.25% and 0.1%, and dithranol ointment 0.25% in the treatment of psoriasis. 636 7

39 patients with bilateral dermatoses, mainly psoriasis vulgaris and atopic dermatitis, were treated with 0.1% Ro 12-7024 ointment and 0.1% betamethasone valerate ointment according to a double-blind, right-left, randomized design. Treatment lasted up to 4 weeks. 5 patients did not complete the trial. Assessment of efficacy, expressed as degree of healing in percent of treated skin area and according to an overall assessment of efficacy made by both physician and patient only revealed marginal, mostly statistically insignificant differences, with a trend in favor of betamethasone. Patients' preferences for one of the two treatments favored betamethasone valerate in 17 cases and Ro 12-7024 in 5 cases; 13 cases were ties (p less than 0.001). With the exception of one case of bilateral erythema and itching no side effects were reported. The efficacy of the D-homosteroid Ro 12-7024 is evidently of the same order as that of the group III steroid betamethasone valerate, and the tolerance of the two ointments is good and equal.
 ...
PMID:A randomized trial on the D-homosteroid domoprednate (Ro 12-7024) in the treatment of dermatoses. 637 Jul 48

We report two cases with adverse cutaneous reactions under lithium medication for manic-depressive disease. The first patient developed follicular keratosis, psoriasiform plaques and seborrheic dermatosis, the second only sclerotic plaques. Cutaneous side-effects that have been associated with lithium therapy include: acneiform eruption, pruritus, maculopapular eruptions, folliculitis, pretibial ulcerations, alopecia...and exacerbation of psoriasis. The exact pathophysiologic mechanism by which lithium induced cutaneous pathology is not completely understood. The various physiologic actions seem to be incomplete in substitution for other extracellular and intracellular cations and interference with cyclic adenosine monophosphate mediated processes.
 ...
PMID:[Cutaneous lesions due to lithium therapy (author's transl)]. 646 94

Hormones of the thyroid gland (thyroxine, tri-iodothyronine) control the metabolism of cells and tissue of the body, while parathormone and calcitonine are balancing the intra- and extracellular levels of calcium and phosphorus by governing some metabolic functions of bones, kidney and small intestine. Growth, maturation and metabolic homeostasis of the organism depend, among other intrinsic factors, on a normal production and secretory rate of both thyroidal and parathyroidal hormones. Clinical conditions of hyperthyroidism induce 1. increased metabolic turnover of the body with transcutaneous heat loss, 2. disordered growth of hairs and nails, 3. hyperpigmentation of skin, 4. pruritus with or without urticaria. Pretibial (usually symmetrical) myxedema may be associated with conditions of either hyper- or hypothyroidism (e.g., Hashimoto's thyroiditis); if combined with bilateral exophthalmus and acropachyderma of fingers and toes, it is called Diamond syndrome, or E.M.O. syndrome. In hypothyroidism, the skin feels chilly and dry, looks pale, and may present follicular keratoses with or without secondary eczema. The hair appears dull and sparse due to disordered anagen phase. Skin wounds heal with delay. Diffuse myxedema originates in the papillary and periadnexal connective tissue and eventually extends to the dermis as a whole. Clinical conditions of hyperparathyroidism rarely cause secondary calcification of the skin; they may induce severe pruritus, particularly in secondary hyperparathyroidism due to renal failure. Impetigo herpetiformis or generalized pustular psoriasis, resp., may be set off by excessive surgical removal of the goiter. Congenital maldevelopment of both thymus and parathyroid gland leads to cellular immune deficiency with secondary chronic muco-cutaneous candidosis.
 ...
PMID:[The thyroid gland, the parathyroid gland and the skin]. 648 58

Two patients with severe generalized psoriasis and psoriatic arthritis whose conditions had failed to respond to oral therapy with traditional remedies, including etretinate (both patients) and its combination with psoralen and UV-A (PUVA) (one patient) were successfully treated with minimal oral dosages of the arotinoid RO 13-6298 (0.05 to 0.1 mg/day). Side effects of this new synthetic retinoid included dryness of the lips and nasal mucosa, some palmarplantar desquamation, gross thinning of the skin, itching, and transient hair loss. Laboratory investigations disclosed no abnormalities attributable to the drug. The new arotinoid, RO 13-6298, seems to be a highly potent retinoid in its antipsoriatic effects. It represents the third generation of synthetic retinoids that may be effective in extremely low doses.
 ...
PMID:Antipsoriatic activity of a new synthetic retinoid. The arotinoid RO 13-6298. 661 62

A retrospective study of 44 cases of generalized pruritus (GP) was undertaken to determine the incidence of systemic disease in this population. This data was compared to that of a group of 44 age- and sex-matched psoriatic controls. We found 13 (30%) of the GP cases to have a systemic disease that in the literature is believed to be associated with GP, versus 10 (23%) in the psoriasis group. Excluding hypothyroidism and diabetes mellitus, two disorders with questionable relationship to GP, the number of pruritus patients with an associated systemic disease was reduced to 8 (18%) compared to only 1 (2%) psoriatic patient, a difference which is statistically significant (p less than 0.02). In 6 (14%) of the GP patients a temporal relationship of systemic disease and GP was suggested. Recommendations for outpatient workup of GP are given. Patient follow-up of 1 to 6 1/2 years revealed that 29 (66%) of the patients had persistent itching. The mean duration of itching to the time of the present follow-up was 57.7 months.
 ...
PMID:Generalized pruritus and systemic disease. 663 May 98

At three University Departments of Dermatology (Berlin, Leipzig, Erfurt) of the GRD, 63 psoriatics (46 men, 17 women) were treated with aromatic retinoid Ro 10-9359 (Tigason) up to a maximum of 84 weeks. In 34 of these cases, photochemotherapy was additionally applied. This combination resulted in a more rapid healing than Tigason alone. The average initial dose amounted to 1 mg per kg body weight. Only in cases of psoriatic erythroderma, the treatment started with a daily rate of 25 mg Tigason. The maintenance dose came to 50 to 25 mg daily. On account of deterioration of the cutaneous condition and/or heavy itching, the treatment had to be discontinued in 4 cases. Side effects as cheilitis, rhagades, loss of hair, and onycholysis disappeared after reduction of the dose. Our study confirmed the good therapeutical effect of Tigason with the various forms of psoriasis.
 ...
PMID:[Psoriasis therapy with the aromatic retinoid Ro 10-9359 (Tigason)]. 663 27


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>